Document is current
Any future updates will be listed below
-
Authors
Albrecht, Andreas P.
Kistler-Fischbacher, Melanie
De Godoi Rezende Costa Molino, Caroline
Armbrecht, Gabriele
Freystaetter, Gregor
Theiler, Robert
Kressig, Reto W.
Da Silva, Jose A. P.
Rizzoli, René
Wanner, Guido A.
Egli, Andreas
Dawson-Hughes, Bess
Bischoff-Ferrari, Heike A. https://orcid.org/0000-0002-4554-658X
-
Funding
Funding for this research was provided by:
European Union, 7th framework (278588)
Universität Zürich
dsm-firmenich AG
ROCHE Diagnostics Switzerland
NESTEC S.A.
Pfizer Consumer Healthcare GmbH
STREULI Pharma AG
Vontobel-Stiftung
University of Zurich
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 1 April 2025
First Online: 25 April 2025
Declarations
:
: HAB-F reports as the PI of the DO-HEALTH trial, grants from the European Commission, (grant agreement no. 278588) from the University of Zurich, from NESTEC, from PFIZER Consumer Healthcare, from Streuli Pharma, plus non-financial support from DSM Nutritional Products and from Roche Diagnostics. Furthermore, HAB-F reports speaker fees from Wild, Pfizer, Vifor, Mylan, Roche Diagnostics, and independent and investigator initiated grants from Pfizer and from Vifor, outside the submitted work. AA, MK-F, CG, GA, GF, RT, RWK, JAPD, RR, GAW, AE, and BD-H declare no conflicts of interest.
